• Combinatorial synthesis and biomarker development
    Patent Application No. 62/313,580, 2016
  • Combinatorial synthesis and biomarker development
    International Patent Application No. PCT/US17/23441, 2017
  • Alzheimer's antigen targets and therapeutic development, 2018


Utility of "proxy antigens" (a special class of biomimetic molecules) is well supported by consistent, independent studies.

For more Information :

Publications on Alzheimer's Clinical Trials

Retrospectively, Alzheimer's disease "proxy antigens" could profile subjects to stratify subsets of drug responders. Prospectively, a simple blood test could identify patients appropriate for such drugs.

Doody, RS et al. N Engl J Med., 370, 311, 2014
Siemers, ER et al. Alzheimer’s & Dementia, 12, 110, 2016

Sevigny, J., et al., Nature, 537, 50-56, 2016.

Kennedy, ME., et al. Sci Transl Med Engl J Med., 8(363), 363, 2016

Ponezumab and Bapineuzumab
La Porte S.L., et al., J Mol Biol., 421(4-5), 525-36, 2011
Salloway S., et al., N Engl J Med., 370(4), 322-33, 2014

Crenezumab and Gantenerumab
Blaettler, T., et al., Alzheimer’s and dementia. 12(7), 609, 2016
Ostrowitzki, s., Arch. Neurol. 69(2), 198, 2012